Docetaxel-cisplatin combined chemotherapy in Japanese patients with anthracycline-pretreated advanced breast cancer.
The aims of this study were to determine the efficacy of docetaxel (DOC) 60 mg/m(2) and cisplatin (CDDP) 80 mg/m(2) combined chemotherapy in Japanese patients with anthracycline-pretreated advanced breast cancer, and to report the side effects of this therapy. Fourteen patients with anthracycline-pretreated advanced breast cancer were enrolled. DOC was administered at 60 mg/m(2) intravenously over at least 1 h, and then CDDP was administered at 80 mg/m(2) intravenously over at least 3 h. Two courses of this regimen were administered at an interval of 3-4 weeks. Two more courses were administered after 6 months if the disease did not progress, or toxicity was acceptable. The overall response (OR) rate was 64.3%. In the patients with metastases, OR was 58.3%, median duration of the response was 31 weeks (range, 6 to 78 weeks), and median overall survival was 85 weeks (range, 35 to >159). Grade 3/4 toxicities were: neutropenia 10/14; anorexia 5/14; nausea/vomiting 3/14; diarrhea 4/14; oral symptoms 1/14. In conclusion, the combination of DOC (60 mg/m(2)) and CDDP (80 mg/m(2)) is an active regimen that can be relatively safely administered to Japanese patients with anthracycline-pretreated advanced breast cancer.
Kariya
Shinji
S
Department of Radiology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.
Ogawa
Yasuhiro
Y
Nishioka
Akihito
A
Yoshida
Shoji
S
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016879:Salvage Therapy; D015996:Survival Rate; D043823:Taxoids
D000903:Antibiotics, Antineoplastic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin